Improving cognition in schizophrenia: Pharmacological and cognitive remediation approaches

Minerva Psichiatrica

Volumn 54, Issue 1, 2013, Pages 1-13

  Harvey, P D ^a   Bowie, C R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Cognition; Pharmacology; Schizophrenia

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ADRENERGIC RECEPTOR; ATOMOXETINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BUSPIRONE; CHOLINERGIC RECEPTOR; DAVUNETIDE; DEXTRO SERINE; DMX B; DONEPEZIL; EVP 6124 009; FLUMAZENIL; GALANTAMINE; GUANFACINE; HISTAMINE RECEPTOR; ISPRONICLINE; LAMOTRIGINE; LORAZEPAM; MK0877; MODAFINIL; NEUROLEPTIC AGENT; PLACEBO; RIMONABANT; RIVASTIGMINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TANDOSPIRONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; BEHAVIOR CHANGE; COGNITION; COGNITIVE REMEDIATION; DISABILITY; DOPAMINE RECEPTOR BLOCKING; EMPLOYMENT; EXERCISE; FUNCTIONAL STATUS; GRAY MATTER; HALLUCINATION; HEALTH PROGRAM; HUMAN; HYPOTENSION; MENTAL PERFORMANCE; META ANALYSIS (TOPIC); NAUSEA; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROTRANSMISSION; PATIENT CARE; PHARMACOKINETICS; PRODUCTIVITY; PROGNOSIS; PSYCHOTHERAPY; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SOCIAL COMPETENCE; TRAUMATIC BRAIN INJURY; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84876542754     PISSN: 03911772     EISSN: 18271731     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin N Am 1993;16:295-312. (Pubitemid 23174755)
2. Bowie CR, Harvey PD. Cognition in schizophrenia:Impairment, determinants, and. functional importance. Psychiatr Clin N Am 2005;28:613-33. (Pubitemid 41191137)
3. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science 2003;299:350-351. (Pubitemid 36120025)
4. Marder SR, Fenton W. Measurement and Treatment Research to improve Cognition in Schizophrenia:NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004;72:5-9. (Pubitemid 39452900)
5. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch, DM, Cohen JD et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-13. (Pubitemid 351704520)
6. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WM, Gold JM et al. The MATRICS consensus cognitive battery: Part 2. Co-norming and standardization. Am J Psychiatry 2008;165:214-220. (Pubitemid 351704521)
7. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WM, Gold JM et al. Functional co-primary measures for clinical trials in schizophrenia.Results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 2008;165:221-8. (Pubitemid 351704522)
8. Moore DJ, Palmer BW, Patterson TL Jeste DV. A review of performance-based measures of everyday functioning. J Psych Res 2007;41:97-118. (Pubitemid 44780756)
9. Patterson, TL, Goldman S, McKibbin CL, Hughs J, Jeste DV. UCSD performance-based skills assessment:Development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001;27:235-45. (Pubitemid 33644299)
10. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley J et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317-31. (Pubitemid 38779804)
11. Leifker FR, Patterson TL, Heaton RK, Harvey PD. Validating measures of real-world outcome: the results of the VALERO Expert Survey and RAND Panel. Schizophr Bull 2011;37:334-43.
12. Harvey PD, Penn D. Social cognition:The key factor predicting social outcome in people with schizophrenia? Psychiatry (Edgmont) 2010;7:41-4.
13. Ventura J, Wood RC, Hellemann GS. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia:A meta-analysis. Schizophr Bull [In press].
14. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573-88.
15. Leifker FR, Bowie CR, Harvey PD. The determinants of everyday outcomes in schizophrenia:Influences of cognitive impairment, clinical symptoms, and functional capacity. Schizophr Res 2009;115:82-7.
16. Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) User's Manual. Toronto: MHS Publishers; 2002.
17. Eack SM, Pogue-Geile MF, Greeno CG, Keshavan MS. Evidence of factorial variance of the Mayer-Salovey-Caruso Emotional Intelligence Test across schizophrenia and normative samples. Schizophr Res 2009;114:105-9.
18. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am J Geriatr Psychiatry 2001;9:340-5. (Pubitemid 33015122)
19. Kahn A. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert Rev Neurother 2008;8:1435-47.
20. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19. (Pubitemid 41214353)
21. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laighren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later? Schizophr Bull 2011;37:1209-17.
22. Medalia A, Revheim N, Herlands T. Cognitive Remediation for Psychological Disorders, Therapist Guide. New York, NY: Oxford University Press; 2009.
23. Bell B, Bryson G, Wexler BE. Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003;108:101-9. (Pubitemid 36801803)
24. Wykes T, Reeder C, Corner J, Williams C, Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 1999;25:291-307. (Pubitemid 29272506)
25. Brenner HD, Hodel B, Roder V, Corrigan P. Treatment of cognitive dysfunction and behavioral deficits in schizophrenia. Schizophr Bull 1992;18:21-6.
26. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald, D, Pogue-Geile MF et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004;61:866-76. (Pubitemid 39181076)
27. Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008;34:483-93.
28. Twamley EW, Savla GN, Zurhellen CH, Heaton RK. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. Am J Psychiatr Rehabil 2008;11:144-63. (Pubitemid 351507794)
29. Fisher M, Holland C, Subramaniam K, Vinogradov S. Neuroplasticity-based cognitive training in schizophrenia: an interim report on effects 6 months later. Schizophr Bull 2010;36:869-79.
30. Popov T, Jordanov T, Rockstroh B, Elbert T, Merzenich MM, Miller GA. Specific cognitive training normalizes auditory sensory gating in schizophrenia:a randomized trial. Biol Psychiatry 2011;69:465-71.
31. Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C et al. Effects on the brain of psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br J Psychiatry 2002;181:144-52. (Pubitemid 34864497)
32. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009;66:549-53.
33. Adcock RA, Dale C, Fisher M, Aldebot S, Genevsky A, Simpson GV et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr Bull 2009;35:1132-41.
34. Bosia M, Bechi M, Marino E, Anselmetti S, Poletti S, Cocchi F et al. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classic rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett 2007;417:271-4. (Pubitemid 46589780)
35. Vinogradov S, Fisher M, Warm H et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009;166:1055-62.
36. Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry 2010;67:674-82.
37. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007;164:1791-802. (Pubitemid 351739231)
38. Dickinson D, Tenhula W, Morris S, Brown C, Peer J, Spencer K et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry. 2010;167:170-80.
39. Rass O, Forsyth JK, Bolbecker AR, Hetrick WP, Breier A, Lysaker PH et al. Computer-assisted cognitive remediation for schizophrenia:a randomized single-blind pilot study. Schizophr Res 2012;139:92-8.
40. Murthy NV, Mahncke H, Wexler BE, Maruff P, Inamdar A et al. Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study. Schizophr Res 2012;139:87-91.
41. Huddy V, Reeder C, Kontis D, Wykes T, Stahl D. The effect of working alliance on adherence and outcome in cognitive remediation therapy. J Nerv Ment Dis. 2012;200:614-9.
42. Choi J, Medalia A. Intrinsic motivation and learning in a schizophrenia spectrum sample. Schizophr Res 2010;118:12-9.
43. Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am J Psychiatry 2012;169:710-8.
44. Lindenmayer JP, McGurk SR, Khan A, Kaushik S, Thanju A, Hoffman L et al. Improving social cognition in schizophrenia:a pilot intervention combining computerized social cognition training with cognitive remediation. Schizophr Bull 2012 [In press].
45. Hooker CI, Bruce L, Fisher M, Verosky SC, Miyakawa A, Vinogradov S. Neural activity during emotion recognition after combined cognitive plus social cognitive training in schizophrenia. Schizophr Res 2012;139:53-9.
46. Wu EQ, Birnbaum HG, Shi L, Hudson T, Kessler RC. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9. (Pubitemid 41442278)
47. McGurk SR, Mueser KT, DeRosa TJ, Wolfe R. Work, recovery, and comorbidity in schizophrenias randomized controlled trial of cognitive remediation. Schizophr Bull 2009;35:319-35.
48. Bell MD, Zito W, Greig T, Wexler BE. Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophr Res 2008;105:18-29.
49. Geyer MA, Tamminga CA. Measurement and treatment research to improve cognition in schizophrenia: Neuropharmacological aspects. Psychopharmacology 2004;174:1-2. (Pubitemid 38925084)
50. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 2009;19:324-35.
51. Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murth A et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder:Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217-28. (Pubitemid 351521707)
52. Sharma TS, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24- week rivastigmine treatment to antipsychotics in schizophrenia:a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006;85:73-83. (Pubitemid 43947524)
53. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2007;165:82-9.
54. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-7.
55. AstraZeneca Global [Internet]. Available at www.astrazeneca.com/ itemid4376018 [cited 2013, Jan 24].
56. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST):The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164:1593-602. (Pubitemid 350069740)
57. Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008;33:465-72.
58. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001;25:402-9. (Pubitemid 32777790)
59. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008;28:59-63.
60. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DM et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011;69:442-9.
61. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001;158:1722-5. (Pubitemid 32923670)
62. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer, HY. Effect of Buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenias randomized, double-blind, placebo-controlled study. Schizophr Res 2007;95:158-68. (Pubitemid 47313647)
63. Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2012;134:207-10.
64. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 2000;57:270-6.
65. Zoccali R, Muscatello MR, Bruno A, Cambria R, Mico U, Spina E et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007;93:109-16. (Pubitemid 46817934)
66. Goff DC, Keefe RSE, Citrome L, Davy, D, Krystal JH, Large C et al. Lamotrigine as add-on therapy in schizophrenia results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007;27:582-9. (Pubitemid 351339444)
67. Morein-Zamir S, Turner DC, Sahakian BJ. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 2007;33:1298-306. (Pubitemid 350022777)
68. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-502. (Pubitemid 351684703)
69. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P et al. Effects of gamma-aminobutyric acidmodulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007;64:156-67. (Pubitemid 46220773)
70. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012;136:25-31.
71. DeLisi LE, Szulc KU, Bertisch HC, Majcher M, Brown K. Understanding structural brain changes in schizophrenia. Dialogues in Clinical Neuroscience 2006;8:71-8.
72. Cahn W, Rais M, Stigter FP, van Haren NE, Caspers E, Hulshoff Pol HE et al. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol 2009;19:147-51.
73. Laruelle M. Dopamine transmission in the schizophrenic brain. In:Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell; 1999. p. 365-87.
74. D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R et al. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology. 2012 [In press].
75. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic P. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 1994;116:143-51. (Pubitemid 24317040)
76. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE, Jr, Jones EG. Maldistribution of interstitial neurons in the prefrontal white matter of brains of schizophrenic patients. Arch Gen Psychiatry 1996;53:425-36. (Pubitemid 26149231)
77. Lim KO, Hedehus M, Moseley M, deCrespigny A., Sullivan EV, Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch Gen Psychiatry 1999;56:367-74. (Pubitemid 29165183)
78. Keefe RSE, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D et al. Report from the Working Group Conference on multi-site trial design for cognitive remediation in schizophrenia. Schizophr But 2011;37:1057-65.
79. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011;168:472-85.
80. Keefe RSE, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC et al. Feasibility and pilot efficacy results from the multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) study. J Clin Psychiatry 2012;73:1016-22.